NCT06139341已完成1 期
Safety, Tolerability, and Pharmacokinetics of Single Rising Intravenous Doses of BI 765845 in Healthy Male Japanese Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Percentage of subjects with treatment-emergent adverse event assessed as drug-related by the investigator
研究概览
简要总结
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 765845 in healthy male Japanese subjects following intravenous administration of single rising doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests at screening visit
- •Japanese ethnicity, according to the following criteria, born in Japan, have lived outside of Japan <10 years, and have parents and grandparents who are Japanese
- •Age of 18 to 45 years (inclusive) at screening visit
- •BMI of 18.5 to 24.9 kg/m2 (inclusive) at screening visit
- •Signed and dated written informed consent in accordance with ICH-Good Clinical Practice (GCP) and local legislation prior to admission to the trial
- •Subjects who agree to minimise the risk of making their partner pregnant by fulfilling any of the following criteria starting from the start of infusion of trial medication until 90 days after end of infusion of trial medication:
- •Use of adequate contraception, any of the following methods plus condom: intrauterine device, combined oral contraceptives that started at least 2 months prior to the first drug administration
- •Vasectomized (vasectomy at least 1 year prior to enrolment)
- •Surgical sterilization (including bilateral tubal occlusion, hysterectomy or bilateral oophorectomy) of the subject's female partner
- •Female partner is postmenopausal, defined as no menses for 1 year without an alternative medical cause
排除标准
- •Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator at screening visit
- •Repeated measurement of systolic BP outside the range of 90 to 140 mmHg, diastolic BP outside the range of 50 to 90 mmHg, or PR outside the range of 50 to 90 bpm at screening visit
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- •Any evidence of a concomitant disease assessed as clinically relevant by the investigator
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders (including any history of cardiovascular diseases such as atherosclerosis, previous myocardial infarction or angina pectoris)
- •Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
- •Diseases of the central nervous system (including but not limited to any kind of seizures or history of stroke), and other relevant neurological or psychiatric disorders
- •History of relevant orthostatic hypotension, fainting spells, or blackouts
研究组 & 干预措施
BI 765845 treatment group
Experimental
干预措施: BI 765845 (Drug)
Placebo group
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of subjects with treatment-emergent adverse event assessed as drug-related by the investigator
时间窗: Up to 73 days
次要结局
- Maximum measured concentration of the analyte in serum (Cmax)(Up to 71 days)
- Area under the concentration-time curve of the analyte in serum over the time interval from 0 extrapolated to infinity (AUC0-∞)(Up to 71 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are ToleratedHealthyNCT05183347Boehringer Ingelheim36
已完成
1 期
A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)HealthyNCT05934955Boehringer Ingelheim24
已完成
1 期
A Study to Test How Well Different Doses of BI 3810477 Are Tolerated by Healthy MenHealthyNCT06631430Boehringer Ingelheim24
终止
1 期
A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are ToleratedHealthyNCT05183360Boehringer Ingelheim48
已完成
1 期
Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male SubjectsHealthyNCT02182388Boehringer Ingelheim82